Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation.
about
The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung diseaseAntimicrobial proteins and polypeptides in pulmonary innate defenceAnti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitorHuman mast cells decrease SLPI levels in type II - like alveolar cell model, in vitroInnate immune defences in the human endometriumThe Role of Serine Proteases and Antiproteases in the Cystic Fibrosis LungAntimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implicationsSecretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritisBeneficial effects of secretory leukocyte protease inhibitor after spinal cord injury.Activation and regulation of NFkappaB during acute inflammation.Regulation of inflammatory vascular damage.Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing.Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration.Secretory leukocyte protease inhibitor plays an important role in the regulation of allergic asthma in mice.Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cellsRegulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafinRegulation of mucosal immunity in the female reproductive tract: the role of sex hormones in immune protection against sexually transmitted pathogensEvaluation of lung injury in rats and mice.Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.Syndecan 4 Mediates Nrf2-dependent Expansion of Bronchiolar Progenitors That Protect Against Lung Inflammation.Novel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis.Estradiol selectively regulates innate immune function by polarized human uterine epithelial cells in cultureInnate host defense functions of secretory leucoprotease inhibitor.Secretory leukocyte peptidase inhibitor and lung cancer.Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens.Proteomic landscape of bronchoalveolar lavage fluid in human immunodeficiency virus infection.CXC chemokines play a critical role in liver injury, recovery, and regeneration.Biological roles of host defense peptides: lessons from transgenic animals and bioengineered tissues.WAP domain proteins as modulators of mucosal immunity.SLPI and elafin: multifunctional antiproteases of the WFDC family.SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions.Acute lung injury and pulmonary vascular permeability: use of transgenic models.Regulatory mechanisms of injury and repair after hepatic ischemia/reperfusionSecretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes.Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding.Adhesion, migration, transcriptional, interferon-inducible, and other signaling molecules newly implicated in cancer susceptibility and resistance of JB6 cells by cDNA microarray analyses.The Ability of Secretory Leukocyte Protease Inhibitor to Inhibit Apoptosis in Monocytes Is Independent of Its Antiprotease Activity.Anti-tumor effect of SLPI on mammary but not colon tumor growth.The effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model.Colloidal gold particles as a new in vivo marker of early acute lung injury.
P2860
Q21146748-148D74DA-B652-4DDB-AE51-86613AC2A036Q24541575-F8FF66CF-2505-4BD0-9C59-FE95CDA8C802Q24681571-39175FB0-D5EA-4B25-B458-E9F18AB8755AQ24799057-E72F67D1-1DFE-49C5-B4FC-8B4C72950F54Q24801159-D0B810F1-1FFE-4AFA-9D72-18FEB7DB25FDQ26799771-E50EFE3E-1BF2-44FF-9C4E-2834573F2C8AQ28087327-02259F76-D2ED-4C66-B6F3-963C543DF1D1Q28572864-C6A2AA74-F561-4BEF-B9BD-D846693E086DQ33570020-FFBD21F4-95A9-49CA-A10D-77B41D88B551Q33649815-22EB6AC4-BB32-4025-82B2-380F9BCFF0B1Q33843576-0233D559-17BB-43DB-A846-386E489F3FE2Q33920067-06CE0985-4F4B-4DB8-8320-4ED864C6DEDCQ34592412-08EC5E83-DB95-4519-867A-B64D2C83EA72Q35014657-F9759355-E821-4076-9081-98A771DD1F13Q35022070-CF890D94-BB83-4804-943E-07361FB9C9E1Q35106451-03663B4F-CD3F-40D4-8BBB-6758D3EEA9F5Q35153994-60B4A70F-2D86-4C4D-8F98-4E67E7A666D9Q35623595-BEBFD067-5FF9-4F41-8E4D-FF8B93FAFE97Q36114167-0C923F44-C335-4236-9A03-63A0D13E822CQ36582808-A61FA966-00FC-4860-9AE3-2E46A3E6CB00Q36735031-FB050628-3ACE-4923-A91C-449FD978C2E6Q36751036-C8B286F3-AC38-48E6-B9B0-0600C4C70E07Q37030651-F8CF83F8-E869-4735-B8A6-25CF0602D5FCQ37124951-4F069D17-9F02-472A-BACC-13A8C27CFA80Q37334338-212CD31F-0118-46B6-BFD4-E0D0B8156484Q37576091-9BEF8B39-764C-4176-9569-DA5C83C3E84BQ37589136-3B6CDAF3-D441-4B2F-9373-9C6F0AAD0E37Q37810793-E6BA5C62-BE80-4809-A5C2-D8D53F96559FQ37936531-D62AAC1E-7A15-44D4-AACE-6D8343020B14Q37936541-C7CBD0AB-321D-41F8-88E7-FC89951536F0Q37936542-5EFD6A2C-EAFB-45C6-89EE-A73002A88DF0Q38112059-EA217628-D571-42F0-B28F-5553E2E293AEQ38166369-50C9AAF7-61BD-4CDB-9F0F-4276210F83D4Q38289011-6C87D9B2-08C5-4D0B-9747-DCBAF58A4639Q38317744-EEBCA1C5-FFBA-47DD-94F6-F07C51D296DBQ38346556-22BF6681-59BD-4B14-ACFF-93E877AF35EBQ38845999-A16A5BE7-D1FE-4862-8FE8-6F2F2A63BBF8Q39318982-C238BEC2-B23D-49AE-A298-AF05D92CC863Q39529387-CE934E36-3DEE-45EA-BD58-C5FD72C4DE44Q39687277-FD3D3683-454F-4E12-9D39-EF739362FBA9
P2860
Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Inhibition of NF-kappaB activa ...... itor during lung inflammation.
@ast
Inhibition of NF-kappaB activa ...... itor during lung inflammation.
@en
type
label
Inhibition of NF-kappaB activa ...... itor during lung inflammation.
@ast
Inhibition of NF-kappaB activa ...... itor during lung inflammation.
@en
prefLabel
Inhibition of NF-kappaB activa ...... itor during lung inflammation.
@ast
Inhibition of NF-kappaB activa ...... itor during lung inflammation.
@en
P2093
P2860
P1476
Inhibition of NF-kappaB activa ...... itor during lung inflammation.
@en
P2093
A B Lentsch
B J Czermak
E M Younkin
J A Jordan
P2860
P304
P356
10.1016/S0002-9440(10)65270-4
P407
P577
1999-01-01T00:00:00Z